Department of Kidney Disease and Blood Purification, The Second Hospital of Tianjin Medical University, Tianjin, China.
Department of Kidney Disease and Blood Purification, The Second Hospital of Tianjin Medical University, Tianjin, China,
Blood Purif. 2020;49(1-2):114-120. doi: 10.1159/000503601. Epub 2019 Dec 12.
Much controversy remains in the literature with respect to whether soluble suppression of tumorigenicity 2 (sST2) can serve to predict all-cause death in patients undergoing maintenance hemodialysis (MHD). This meta-analysis therefore sought to analyze extant datasets exploring the association between these 2 variables in MHD patients in order to draw relevant conclusions.
Articles published through December 2018 in PubMed and Embase were independently reviewed by 2 authors to identify relevant articles, and STATA 12.0 was used for statistical analyses of relevant results and study parameters.
In total, we identified 4 relevant studies that were incorporated into this meta-analysis. These studies included a total of 1,924 participants (60% male, mean follow-up 911 days). The combined study results suggested that increased levels of sST2 were significantly linked to a 2.23 fold rise in all-cause mortality (hazard ratio [HR] 2.23, 95% CI 1.81-2.75). Subgroup analyses confirmed that this same association was true in patients undergoing hemodialysis (HR 2.17, 95% CI 1.74-2.71), which indicated that the increased levels of sST2 were significantly linked to a 2.17 fold rise in all-cause mortality.
This analysis suggests that there is a significant link between elevated levels of sST2 and death in patients undergoing MHD. Further large-scale trials, however, will be needed to fully validate these findings and their clinical relevance.
在接受维持性血液透析（MHD）的患者中，可溶性抑制肿瘤发生 2 型（sST2）是否可以预测全因死亡，文献中仍存在很大争议。因此，这项荟萃分析旨在分析现有的数据集，以探讨 MHD 患者中这两个变量之间的关系，从而得出相关结论。
由两位作者独立查阅 PubMed 和 Embase 数据库中截至 2018 年 12 月发表的文章，以确定相关文章，并使用 STATA 12.0 对相关结果和研究参数进行统计分析。
共纳入 4 项相关研究，共计 1924 名参与者（60%为男性，平均随访时间为 911 天）。汇总研究结果表明，sST2 水平升高与全因死亡率升高 2.23 倍显著相关（风险比[HR]2.23，95%可信区间 1.81-2.75）。亚组分析证实，这种相关性在接受血液透析的患者中也是成立的（HR 2.17，95%可信区间 1.74-2.71），表明 sST2 水平升高与全因死亡率升高 2.17 倍显著相关。
本分析表明，MHD 患者 sST2 水平升高与死亡之间存在显著关联。然而，需要进一步的大规模试验来充分验证这些发现及其临床意义。
